Checkpoint and PARP inhibitors, for whom and when.
作者信息
Lee Jung-Min, Gulley James L
机构信息
Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
出版信息
Oncotarget. 2017 Sep 12;8(56):95036-95037. doi: 10.18632/oncotarget.20852. eCollection 2017 Nov 10.
Abstract
摘要
相似文献
1
Checkpoint and PARP inhibitors, for whom and when.
Oncotarget. 2017 Sep 12;8(56):95036-95037. doi: 10.18632/oncotarget.20852. eCollection 2017 Nov 10.
2
Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Hum Pathol. 2013 Aug;44(8):1638-47. doi: 10.1016/j.humpath.2013.01.015. Epub 2013 Apr 8.
3
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28.
4
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Cancer Immunol Res. 2015 Nov;3(11):1257-68. doi: 10.1158/2326-6066.CIR-15-0044. Epub 2015 Jul 2.
5
The current status of PARP inhibitors in ovarian cancer.
Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
6
PARP inhibitors in ovarian cancer: current status and future promise.
Gynecol Oncol. 2014 May;133(2):362-9. doi: 10.1016/j.ygyno.2014.02.039. Epub 2014 Mar 4.
7
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Future Oncol. 2015;11(5):747-57. doi: 10.2217/fon.14.313.
8
"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.
Oncotarget. 2017 Apr 4;8(14):23891-23904. doi: 10.18632/oncotarget.14409.
9
Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
CA Cancer J Clin. 2017 Nov;67(6):493-506. doi: 10.3322/caac.21408. Epub 2017 Sep 7.
10
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Curr Oncol Rep. 2016 May;18(5):29. doi: 10.1007/s11912-016-0515-z.
引用本文的文献
1
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol. 2023 Feb;24(2):162-174. doi: 10.1016/S1470-2045(22)00739-2. Epub 2023 Jan 6.
2
Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
Oncogene. 2022 Nov;41(46):5020-5031. doi: 10.1038/s41388-022-02491-8. Epub 2022 Oct 12.
3
Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms.
J Immunother Precis Oncol. 2020 Feb 10;3(1):3-15. doi: 10.4103/JIPO.JIPO_1_20. eCollection 2020 Feb.
4
The Multifactorial Role of PARP-1 in Tumor Microenvironment.
Cancers (Basel). 2020 Mar 20;12(3):739. doi: 10.3390/cancers12030739.
5
The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
Urol Oncol. 2019 Aug;37(8):543-555. doi: 10.1016/j.urolonc.2018.10.011. Epub 2018 Nov 13.
6
Update on PARP Inhibitors in Breast Cancer.
Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2.
本文引用的文献
1
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.
2
PARP inhibitors: Synthetic lethality in the clinic.
Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16.
3
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720. doi: 10.1158/1078-0432.CCR-16-3215. Epub 2017 Feb 6.
4
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing.
Nat Immunol. 2016 Sep 20;17(10):1142-9. doi: 10.1038/ni.3558.
5
Classifying Cancers Based on T-cell Infiltration and PD-L1.
Cancer Res. 2015 Jun 1;75(11):2139-45. doi: 10.1158/0008-5472.CAN-15-0255.
6
Advances in the understanding of cancer immunotherapy.
BJU Int. 2015 Sep;116(3):321-9. doi: 10.1111/bju.12692. Epub 2015 May 18.
7
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
Clin Cancer Res. 2011 Jun 15;17(12):3884-91. doi: 10.1158/1078-0432.CCR-10-2656.
8
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Nat Med. 2004 Sep;10(9):942-9. doi: 10.1038/nm1093. Epub 2004 Aug 22.
Zotero 插件